U.S. House Oversight Cmte Chair
- Gilead announced it will charge govt programs $390 per vial, or $2,340 per five-day treatment of the drug, joint statement says
- “Because of the high price,” the lawmakers are asking GAO to also examine what legal rights federal agencies have related to their contributions to the discovery and development of remdesivir: statement
- Link to letter
- NOTE: Stabenow is top Democrat on Senate Finance Cmte health panel
To contact the reporter on this story: